Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
- Combination Cancer Immunotherapy Market Opportunity: > USD 15 Billion
- Combination Cancer Immunotherapy Market By 15 Different Cancers
- Insight On Clinically & Commercially Approved Cancer Immunotherapy Combinations
- Patent, Price & Dosage Analysis On Approved Combination Drugs
- Global & Regional Sales Insights On Approved Combination Drugs Till 2028
- Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
- Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
- Clinical Trials & Patent Insight By Company, Country, Indication & Phase
In recent times, immunotherapy has emerged out to be most exciting paradigm change in cancer treatment. Since its initial approval, it has become the standard mode of treatment for wide range of malignancies. Due to their targeted nature and less associated side effects, pharmaceutical companies have invested huge amount to develop novel immunotherapeutic approaches in cancer treatment. Till now, a cocktail of immunotherapeutic approaches have gained approval in the treatment of cancer including therapeutic antibodies, vaccines, immune checkpoint inhibitors, cell therapies and others. To further enhance their efficacy researchers have initiated clinical trials evaluating novel combination therapies.
Currently, a cocktail of drugs have been approved as combination therapy for the management of cancer which are showing robust adoption rates in the global market. For instance in 2022, in March 2022, US FDA has granted approval to relatlimab, a novel LAG-3 inhibitor in combination with nivolumab. The drug is sold under the brand name Opdualag and is marketed by Bristol Myers Squibb. Recently in July 2022, Bristol Myers Squibb nnounced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has also granted market authorization to the drug. This has also propelled the further research and development activities in this domain.
Recently in 2022, Tres Bio initiated phase-II clinical trial evaluating the off-the-shelf immunotherapy PolyPEPI1018 with Roche’s anti-PD-L1 drug Tecentriq (atezolizumab) in colorectal cancer patients. The study’s primary goal is to assess the safety and tolerability of the immunotherapy combination, and the secondary aims include evaluating objective response rates, duration of response, progression-free survival, and overall survival. Further, BioNTech has dosed first patient in phase-II clinical trial evaluating its mRNA-based therapy BNT111 in combination with Libtayo (cemiplimab) in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma. Apart from this, more than 10,000 clinical trials are ongoing in the market which is evaluating novel combinations across wide range of cancer.
The major players in the global combinational immunotherapy market include Amgen, Roche, Macrogenics, Mylan, Seagen, AstraZeneca, Gilead Sciences, GlaxoSmithKline, and others. These pharmaceutical giants have also initiated several collaborative deals which will have a positive impact on the growth of market. For example, UbiVac has collaborated with Bristol Myers Squibb to evaluate the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product, DPV-001™, a first-in-class cancer vaccine that exploits autophagy, in combination with Bristol Myers Squibb’s anti-OX40 (BMS-986178) combined with sequenced administration of the programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo (nivolumab). Another, Oxford BioTherapeutics and Agenus are conducting clinical trial evaluating the combination of OBT076 with the anti-PD1 checkpoint inhibitor (CPI) balstilimab.
Further, regulatory bodies are also granting several designations which is boosting the approval process for novel combination cancer immunotherapy. Ultimovacs has developed universal cancer vaccine, UV-1 which consists of three long peptides covering the active site of the tumor associated antigen telomerase. Through vaccination, patients can elicit telomerase specific T cells which have the potential of providing necessary inflammatory tumor microenvironment for optimal immune mediated tumor control. Currently, the company is undergoing several phase-I/II clinical trials as monotherapy or combination therapy across wide range of cancers. In 2021, US FDA has granted fast track designation to the universal cancer vaccine UV1 in combination with immune checkpoint inhibitors in patients with unresectable or metastatic melanoma, either as an add-on therapy to pembrolizumab or ipilimumab. The designation is based on encouraging phase-II clinical trial where the combination was found to be safe and elicit early efficacy. As per our report findings, the global combination cancer immunotherapy market is expected to surpass US$ 15 Billion by 2028.